Paradigm Biopharmaceuticals 과거 수익 실적

과거 기준 확인 0/6

Paradigm Biopharmaceuticals의 수입은 연평균 -29.1%의 비율로 감소해 온 반면, Biotechs 산업은 수입이 연평균 13.3%의 비율로 증가했습니다. 매출은 연평균 73.9%의 비율로 감소해 왔습니다.

주요 정보

-29.1%

수익 성장률

-19.5%

EPS 성장률

Biotechs 산업 성장	9.6%
매출 성장률	-73.9%
자기자본 수익률	-246.4%
순이익	n/a
최근 수익 업데이트	30 Jun 2024

최근 과거 실적 업데이트

Recent updates

Paradigm Biopharmaceuticals (ASX:PAR) Is In A Strong Position To Grow Its Business

Aug 22

Here's Why We're Not At All Concerned With Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Apr 17

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Sep 21

Here's Why We're Not Too Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Jun 20

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Dec 02

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Jun 07

Is Paradigm Biopharmaceuticals Limited (ASX:PAR) Trading At A 46% Discount?

Feb 22

We're Not Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn

Jan 24

Did You Participate In Any Of Paradigm Biopharmaceuticals' (ASX:PAR) Incredible 811% Return?

Dec 28

When Will Paradigm Biopharmaceuticals Limited (ASX:PAR) Turn A Profit?

Nov 29

수익 및 비용 분석

Paradigm Biopharmaceuticals 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

ASX:PAR 수익, 비용 및 수입 (AUD Millions )
날짜	수익	수익	G+A 비용	R&D 비용
30 Jun 24	0	-59	7	58
31 Mar 24	0	-64	6	65
31 Dec 23	0	-69	6	71
30 Sep 23	0	-60	7	62
30 Jun 23	0	-52	7	53
31 Mar 23	0	-48	9	48
31 Dec 22	0	-44	10	43
30 Sep 22	0	-42	9	41
30 Jun 22	0	-39	9	39
31 Mar 22	0	-40	9	39
31 Dec 21	0	-41	10	40
30 Sep 21	0	-37	10	37
30 Jun 21	0	-34	10	34
31 Mar 21	0	-31	7	30
31 Dec 20	-1	-28	5	27
30 Sep 20	0	-20	4	20
30 Jun 20	0	-12	3	14
31 Mar 20	2	-14	4	12
31 Dec 19	4	-16	4	9
30 Sep 19	3	-16	4	8
30 Jun 19	3	-16	4	8
31 Mar 19	3	-11	3	7
31 Dec 18	3	-7	3	7
30 Sep 18	3	-7	2	7
30 Jun 18	3	-6	2	7
31 Mar 18	2	-6	2	6
31 Dec 17	2	-5	2	5
30 Sep 17	2	-5	2	5
30 Jun 17	2	-4	2	4
31 Mar 17	2	-4	2	4
31 Dec 16	1	-4	2	4
30 Sep 16	1	-4	2	3
30 Jun 16	1	-3	1	3
31 Mar 16	1	-3	2	2
31 Dec 15	0	-2	1	1
30 Sep 15	0	-2	1	1
30 Jun 15	0	-2	1	0

양질의 수익: PAR 은(는) 현재 수익성이 없습니다.

이익 마진 증가: PAR 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: PAR 은(는) 수익성이 없으며 지난 5년 동안 연간 29.1% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 PAR 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: PAR 은(는) 수익성이 없어 지난 해 수익 성장을 Biotechs 업계( 7.4% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: PAR 현재 수익성이 없기 때문에 마이너스 자본 수익률( -246.38% )을 갖습니다.

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/31 11:11
장 마감 주가	2024/12/31 00:00
수익	2024/06/30
연간 수익	2024/06/30

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Paradigm Biopharmaceuticals Limited 4 애널리스트 중 1 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
John Hester	Bell Potter
Soo Romanoff	Edison Investment Research
Arron Aatkar	Edison Investment Research

Paradigm Biopharmaceuticals 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

Paradigm Biopharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 16 million.

New major risk - Revenue and earnings growth

New major risk - Share price stability

Donna Skerrett Steps Down from Position as an Executive Director on the Board of Paradigm Biopharmaceuticals Ltd

Paradigm Biopharmaceuticals Ltd Plans to Submit the Finalized Protocol for Its Phase 3 Clinical Trial

Non-Executive Director recently bought AU$73k worth of stock

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 19, 2024

New minor risk - Profitability

Insufficient new directors

New minor risk - Share price stability

New minor risk - Shareholder dilution

New minor risk - Market cap size

New minor risk - Share price stability

Paradigm Biopharmaceuticals Ltd Announces Resignation of John Gaffney as Independent Non Executive Director, Effective Immediately

Consensus EPS estimates fall from profit to AU$0.18 loss

Forecast breakeven date pushed back to 2025

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 29, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Paradigm Biopharmaceuticals (ASX:PAR) Is In A Strong Position To Grow Its Business

Founder recently bought AU$76k worth of stock

Here's Why We're Not At All Concerned With Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Paradigm Biopharmaceuticals Ltd Advises the First Safety Review Meeting of the Data Monitoring Committee (DMC) for the Pivotal Para_OA_002 Clinical Trial

Founder recently bought AU$62k worth of stock

Paradigm Biopharmaceuticals Limited Announces Executive Changes

Price target increased to AU$2.20

Paradigm Biopharmaceuticals Limited Announces an Abstract on Paradigm's Phase 2 Clinical Trial Evaluating Injectable Pentosan Polysulfate Sodium

Paradigm Biopharmaceuticals Limited Announces First UK Subject Randomised and Dosed for the Pivotal Phase 3 Trial for the Treatment of Pain Associated with Knee OA

Paradigm Biopharmaceuticals Ltd Announces Successful Primary Endpoint in Phase 2 Trial

Paradigm Biopharmaceuticals Ltd Provides an Update on the Ongoing Multi-Centre Double-Blind Randomised Phase 2 Study Comparing PPS to Placebo in Mucopolysaccharidosis Type VI (MPS-VI) Patients

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 18, 2022

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Paradigm Biopharmaceuticals Limited Appoints Abby Macnish as Interim Company Secretary

Paradigm Biopharmaceuticals Ltd Announces MPS Clinical Program Update and Paradigm to Present At the International Conference on Lysosomal Diseases

Paradigm Biopharmaceuticals Limited Reports Important Global Progress for the Para_Oa_002 Phase 3 Clinical Trial Evaluating Zilosul® for Osteoarthritis

Paradigm Biopharmaceuticals Limited Announces PARA_OA_008 Study Evaluating Zilosul® Mechanism and Disease Modifying Effects Completes Recruitment

Forecast to breakeven in 2024

Here's Why We're Not Too Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Paradigm Biopharmaceuticals Limited Announces Chief Executive Officer Changes

Paradigm Biopharmaceuticals Limited Doses First US Subjects Under Phase 3 Trial

Price target decreased to AU$2.64

U.S. Food and Drug Administration Grants Fast Track Designation for Paradigm Biopharmaceuticals Ltd of Phase 3 Program

Founder & Non-Executive Chairman recently bought AU$51k worth of stock

Price target increased to AU$4.49

Consensus forecasts updated

No longer forecast to breakeven

Paradigm Biopharmaceuticals Limited Announces First Subjects Randomised and Dosed in Para_0A_002 Phase 3 Study in Australia

Paradigm Biopharmaceuticals Ltd Reports Postive Topline Results in Heart Failure Model

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Paradigm Biopharmaceuticals Limited Reports Preliminary Results from Phase 2 Mps I Study

Paradigm Biopharmaceuticals Limited Announces First MPS-VI Patient Dosed Under Phase 2 Trial in Brazil Investigating PPS for the Treatment of MPS-VI

Paradigm Biopharmaceuticals Limited Receives Feedback from US FDA on IND Submission

Paradigm Biopharmaceuticals Limited Announces Australian Ethics Approval for Paradigm's ARA_OA_002 Pivotal Phase 3 Clinical Trial in Participants with Knee OA

Paradigm Biopharmaceuticals Limited Makes Progress with Investigational New Drug Application

Consensus EPS estimates increase to -AU$0.15

Paradigm Biopharmaceuticals Limited Receives Key Regulatory Approvals for MPS VI Study

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Paradigm Biopharmaceuticals Ltd Receives First Revenue Through Physician Prescription of Zilosul to Patients Via the TGA SAS

Paradigm Biopharmaceuticals Ltd Provides an Update on its IND Application to the Us Food and Drug Administration

Paradigm Biopharmaceuticals Limited Updates Phase 2A, Randomised, Double-Blind, Placebo- Controlled Study

Analysts lower EPS estimates to -AU$0.17

New 90-day low: AU$2.28

Is Paradigm Biopharmaceuticals Limited (ASX:PAR) Trading At A 46% Discount?

Paradigm Biopharmaceuticals Ltd Announces It Has Received Ethics Approval for Its Phase 2 Clinical Trial to Evaluate the Treatment Effects of Pentosan Polysulfate Sodium

Paradigm Biopharmaceuticals Limited Appoints Helen Fisher as Non-Executive Director and Chair of the Audit and Risk Committee

Paradigm Biopharmaceuticals Ltd Reports Ongoing Data Update on Patients Who Received Zilosul Under the Therapeutic Goods Administration (TGA) Special Access Scheme

We're Not Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn

New 90-day low: AU$2.38

New 90-day low: AU$2.44

Did You Participate In Any Of Paradigm Biopharmaceuticals' (ASX:PAR) Incredible 811% Return?

Paradigm Biopharmaceuticals Ltd Receives the Written Response from the Type-C meeting with the US Food and Drug Administration (FDA) regarding Zilosul® for the Treatment of Osteoarthritis

When Will Paradigm Biopharmaceuticals Limited (ASX:PAR) Turn A Profit?

Paradigm Biopharmaceuticals Limited Announces Resignation of Chris Fullerton as Non- Executive Director

New 90-day high: AU$3.13

Paradigm Biopharmaceuticals Limited Announces First Patient Dosed in Phase 2 Clinical Trial Evaluating PPS in Mucopulysaccharidoses Type-1